Clinical Trial

KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is an interventional Phase II clinical trial aiming to optimize immunotherapy strategies for microsatellite-stable colorectal cancer. We will include three types of metastatic colorectal cancer patients: those without liver metastasis, or carrying BRAF V600E mutation, or unable to tolerate chemotherapy as their initial or second-line treatment. The participants will receive a combination treatment of regorafenib and KN046 which is a PD-L1/CTLA-4 bispecific antibody. Treatment efficacy and safety profile would be evaluated in this study.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-08-02; most recent amendment 2023-10-25.
Status change: Not Yet Recruiting → Recruiting 2023-08-26
Trial Details
NCT Number NCT05985109
Lead Sponsor Peking University Cancer Hospital & Institute
Conditions Colorectal Cancer
Enrollment 98 participants
Start Date 2023-10-26
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-10-26